

Proposed Project Scope

Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Date: December 2023

Background and Rationale

CADTH received a request from public drug programs for a Non-Sponsored Reimbursement Review of mepolizumab for eosinophilic granulomatosis with polyangiitis (EGPA).

Table I: Policy Questions

Item	Policy Question
1	Should mepolizumab be publicly reimbursed for eosinophilic granulomatosis with polyangiitis (EGPA)?

Table II: Products Available in Canada

Product	Manufacturer
Mepolizumab (Nucala) 100 mg/mL	GlaxoSmithKline Inc

Project Description

Table III: Project Scope

Criteria	Description
Population	Adult (≥18 years) patients with eosinophilic granulomatosis with polyangiitis (EGPA)
Intervention(s)	Mepolizumab
Comparators	Placebo, glucocorticoid monotherapy, cyclophosphamide, rituximab, methotrexate, azathioprine, mycophenolate.
Outcomes	<ul style="list-style-type: none"> Remission measured by Birmingham Vasculitis Activity Score (BVAS) (BVAS) Oral corticosteroid (OCS) requirement/dose Recurrence/relapse Hospitalization ACQ-6 score Quality of life
	Harms <ul style="list-style-type: none"> Adverse events

Table IV: Research Questions

Item	Policy Question
1	What is the effectiveness of mepolizumab for eosinophilic granulomatosis with polyangiitis (EGPA)?
2	What are the harms associated with mepolizumab for eosinophilic granulomatosis with polyangiitis (EGPA)?
3	What is the expected cost of mepolizumab for eosinophilic granulomatosis with polyangiitis (EGPA) vs. other reimbursed regimes?

Key Project and Protocol Components

This project will follow the [Procedures for Non-Sponsored Reimbursement Reviews](#).

Status of the Document

This proposed project scope is being posted for information.